Rx · Prescription onlyInjected under the skin
MOTS-c
Mitochondrial energy.
Your plan
$209/mo, $1,254 billed once for 6 months/mo
$1,254 billed once for 6 months · unused months refunded on a medical stop
No membership fee · this is the full price · free shipping · avg 4-week supply
- Medication, clinician care and dose adjustments, all in one price.
- ~28-day supply. Your clinician sets your exact dose, so yours may vary; your refill arrives as you finish the last one.
A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.
FDA status: Compounded medication, not FDA-approved.
What it's for
Who it's for
Adults interested in metabolism and exercise capacity rather than growth hormone.
How it's different
A peptide made by the mitochondria. It does not touch growth hormone at all.
How it works
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, the small genome inside the energy-producing parts of your cells. It acts as a signal between mitochondria and the rest of the cell, activating AMPK, the energy sensor that exercise also switches on. Levels fall with age and with metabolic disease.
How to use it and what arrives
1 vial · lasts 4 weeks
2 mg/mL · 5 mL vial
- How
- Injected under the skin
- How often
- 5 days a week
- When
- In the morning
Good to know
It can lower blood sugar. If you take diabetes medicine, your clinician needs to know before you start.
What the research shows
A 16-amino-acid peptide encoded in mitochondrial DNA. The main evidence is from mice; no published human trial of MOTS-c itself was found.
Obese mice
less weight gain
In male mice on a high-fat diet, daily injections of 0.5 mg/kg for eight weeks prevented diet-induced obesity and insulin resistance.
Lee et al., Cell Metabolism 2015Muscle
insulin sensitivity in mice
The paper names skeletal muscle as the main target organ. Clamp studies in the same mouse work showed better whole-body insulin sensitivity after treatment. The effect was shown in mice, not people.
Lee et al., Cell Metabolism 2015Human data
no MOTS-c trial found
The only human data come from CB4211, an analogue of MOTS-c, in a 2021 company-announced Phase 1a/1b study. It was well tolerated, injection-site reactions were the most common side effect, and liver enzymes fell in an exploratory analysis. It is not MOTS-c.
CohBar, CB4211 Phase 1a/1b topline results, August 10, 2021
The mouse studies used injected peptide at doses that do not translate directly to people. The human results above are for an analogue and come from a company release; we did not find a peer-reviewed publication of that trial.
What this does not say
- We found no human trial of MOTS-c itself.
- Most mouse data come from one research group.
- The blend also contains tesamorelin, which has its own evidence (see its page); We found no trial of the two together.
Sources
- Ipamorelin, the first selective growth hormone secretagogue: release of growth hormone without cortisol or prolactin. Eur J Endocrinol, 1998
- Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 2006
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 2015
- Metabolic effects of a growth hormone-releasing factor (tesamorelin): randomized trial showing reduced visceral fat. N Engl J Med, 2007
- Effects of tesamorelin on non-alcoholic fatty liver disease: randomised, double-blind, multicentre trial. Lancet HIV, 2019
Safety
FDA status: Compounded medication, not FDA-approved.
Side effects and precautions
- Growth hormone-releasing peptides are generally well tolerated.
- Common, mild effects include redness or a small bump at the injection site, headache, flushing, water retention, tingling in the hands or joint aches in the first weeks, and vivid dreams as sleep deepens.
- MOTS-c may change blood sugar responses: tell your clinician if you take diabetes medication.
Get care right away
- Stop and seek care for hives, swelling of the face or lips or trouble breathing.
When it isn't prescribed
- They are not prescribed with an active cancer, a cancer under evaluation, uncontrolled diabetes, or during pregnancy or breastfeeding, and they are used with care in people with a history of pituitary disease.
Tell your clinician about every medication you take.
Questions
Is MOTS-c a growth hormone peptide?
No. MOTS-c works on cellular energy metabolism through AMPK, not on the pituitary. It is grouped with our metabolic peptides because it is often used alongside growth hormone-releasing peptides for body composition and energy. Your clinician decides whether it fits your goals.
How do I take it?
A small subcutaneous injection with an insulin-style needle, most often at night before bed, on an empty stomach. Your clinician sets the dose and schedule; MOTS-c is often a few times a week rather than nightly. The kit includes everything.
Is this the same as HGH?
No. These peptides prompt your pituitary to release your own growth hormone in its natural pulses, so the body's feedback loops stay in control. Synthetic HGH bypasses those loops. That difference is why the side-effect profile is milder.
What are the side effects?
Mild for most people: injection-site redness, headache, flushing, water retention, tingling or joint aches in the first weeks, and vivid dreams. Not prescribed with an active or suspected cancer or in pregnancy. Read the safety information above.
Ready to start with MOTS-c?
$209/mo · $1,254 billed once for 6 months
- Free shipping on every order
- No membership fee
- Same price at every dose
- HSA and FSA accepted
